CryoLife Q4 Adjusted Profit Misses Street Mark, Revenues Just Higher

CryoLife (CRY), a manufacturer of medical devices and implantable tissues, reported late Wednesday Q4 adjusted profit of $0.05 per share, down from $0.14 per share in the prior year period and lower than the $0.11 per share Street estimate provided by Capital IQ.

Revenue for the quarter was $67.8 million, up from $52.8 million reported for the same period last year and just higher than the $67.1 million Street estimate.

For 2019, the company expects adjusted earnings of $0.28 to $0.32 per share on revenues of between $280 million to $284 million.